Prosecution Insights
Last updated: November 04, 2026
Application No. 18/786,850

COSMETIC COMPOSITION, COSMETIC, METHOD FOR APPLYING COSMETIC COMPOSITION, AND METHOD FOR APPLYING COSMETIC

Non-Final OA §103§112
Filed
Jul 29, 2024
Priority
Oct 17, 2023 — JP 2023-178555
Examiner
WEBB, WALTER E
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Under7 Co. Ltd.
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
1y 0m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
465 granted / 1005 resolved
-13.7% vs TC avg
Strong +19% interview lift
Without
With
+18.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
56 currently pending
Career history
1065
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
52.1%
+12.1% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
16.3%
-23.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1005 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Invention I, Claims 1-4, 17-18, in the reply filed on 08/21/2026 is acknowledged. Claims 5-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 3-4 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 3 requires concentrations of tartaric acid, glycine, Na citrate, alanine, 2Na succinate, and Na sulfate that are different from what is required in the independent claim 1. Accordingly, claim 3 does not further limit the independent claim. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-4, 17-18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Tang et al. (Molecules, 2018), Singh (Minimalist, 2020), Seitz (WO 02/078667), and further in view of Kopilow et al., (US 5,169,622). Tang et al. teaches the dual effects of alpha-hydroxy acids (AHAs) on skin. AHA’s like “tartaric acid” are used “extensively in cosmetic formulations” and “have been used as superficial peeling agents as well as to ameliorate the appearance of keratoses and acne in dermatology” (Abstract). “In chemical peeling, AHAs are used in exposure time intervals such as 35% (4 min), 52.5% (3 min), 70% (2 min) at varying intervals for up to 6 months” (p. 2, last paragraph). Here the reference provides motivation for using tartaric acid in a cosmetic composition in an amount of 57.07% or 57% (claim 3) insofar as it is within the scope of usage as a chemical peel. Accordingly, it would have been obvious to apply the cosmetic to the skin, as per claims 17-18. Tang does not teach other claimed ingredients such as amino acids. Sing teaches the role of amino acids in skin care, identifying “11 non-essential amino acids”, i.e. “alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, proline, serine, and tyrosine” (page 1, 8th paragraph) and “nine essential amino acids”, i.e., “histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine” (Id. 11th paragraph), as per claims 1-4. “Topical products containing amino acids fortify the natural defense mechanism of our skin and improve its texture” (page 2, last paragraph). These amino acids also promote healing insofar as the reference teaches, “They repair and replace the damaged proteins in your skin. Mostly, they are known to boost the process of wound healing and closure” (page 3, 5th paragraph). Here, it would have been reasonable to combine amino acids, like glycine and alanine, with the chemical peel of Tang for the advantage of boosting skin repair and improving skin texture, as taught by Singh. The combination of Tang et al. and Singh does not teach disodium succinate, sodium sulfate, or sodium citrate. Seitz teaches compositions for the care of skin (Abstract), comprising a “hydrotrope”, which “is a compound that has the ability to enhance the water solubility of other compounds”, where hydrotropes include “disodium succinate” (p. 34, lines 5-18). Hydrotropes may be present from “about 1% to about 40%, by weight” (p. 33, line 19). The compositions also comprise humectants, which may be present from “0% to about 2%” such as “sodium lactate” “sodium PCA”, “PCA” (p. 37, lines 15-33) and “water” as a carrier (p. 38, lines 18-19), as per claim 4. Kopolow et al. teaches hair and skin compositions (Abstract) comprising “sodium citrate” and “sodium sulfate”, as “optional components suitable for rendering such compositions more acceptable”, which may be present “from about 0.01% to about 10%” (Id. lines 8-34). Generally, it is prima facie obvious to select a known material based on its suitability for its intended use (see MPEP 2144.07). Also, established precedent holds that it is generally obvious to add known ingredients to known compositions with the expectation of obtaining their known function (see 2144.06). In this case, it would have been obvious to a person having ordinary skill in the art to combine the ingredients as claimed in order to make a cosmetic for treating the skin in view of the prior art. The artisan would have been motivated to provide tartaric acid in the claimed amount for is ability to chemically peel the skin. The amino acids would have been added for the advantage of tissue repair and improved texture. The addition of disodium succinate, sodium citrate, and sodium sulfate would have been advantageous for rendering compositions more acceptable, as taught by Seitz and Kopolow et al. It is noted that the prior art is silent as to the amounts of amino acid present in the composition; however, because the presence of amino is taught it would have been obvious to optimize the range of amino acid, especially given its function for treating skin. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Conclusion Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WALTER E WEBB whose telephone number is (571)270-3287 and fax number is (571) 270-4287. The examiner can normally be reached from Mon-Fri 7-3:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Walter E. Webb /WALTER E WEBB/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Jul 29, 2024
Application Filed
Sep 21, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778860
Delivery Carrier For Tooth Whitening
4y 11m to grant Granted Nov 03, 2026
Patent 12778874
Catalase Composition with Improved Stability and Methods
4y 1m to grant Granted Nov 03, 2026
Patent 12773379
METHODS OF USE OF ORAL CARE COMPOSITIONS COMPRISING HOPS
2y 5m to grant Granted Oct 27, 2026
Patent 12758476
ACID RESISTANT COMPOSITION HAVING IMPROVED SOLUBILITY
4y 4m to grant Granted Oct 13, 2026
Patent 12758483
ANTIBACTERIAL AND MINERALIZING COMPOSITIONS AND METHODS OF USE THEREOF
3y 1m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
65%
With Interview (+18.8%)
3y 4m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1005 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month